相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。New β-lactam-β-lactamase inhibitor combinations in clinical development
David M. Shlaes
ANTIMICROBIAL THERAPEUTICS REVIEWS: THE BACTERIAL CELL WALL AS AN ANTIMICROBIAL TARGET (2013)
Ceftazidime-Avibactam: a Novel Cephalosporin/beta-lactamase Inhibitor Combination
George G. Zhanel et al.
DRUGS (2013)
Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial
Christopher Lucasti et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2013)
Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study
Jose A. Vazquez et al.
CURRENT MEDICAL RESEARCH AND OPINION (2012)
Avibactam is a covalent, reversible, non-β-lactam β-lactamase inhibitor
David E. Ehmann et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Activities of NXL104 Combinations with Ceftazidime and Aztreonam against Carbapenemase-Producing Enterobacteriaceae
David M. Livermore et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Activity of NXL104 in Combination with β-Lactams against Genetically Characterized Escherichia coli and Klebsiella pneumoniae Isolates Producing Class A Extended-Spectrum β-Lactamases and Class C β-Lactamases
P. R. S. Lagace-Wiens et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Diazabicyclooctanes (DBOs): a potent new class of non-β-lactam β-lactamase inhibitors
Ken Coleman
CURRENT OPINION IN MICROBIOLOGY (2011)
Mechanistic Studies of the Inactivation of TEM-1 and P99 by NXL104, a Novel Non-β-Lactam β-Lactamase Inhibitor
Therese Stachyra et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Current Challenges in Antimicrobial Chemotherapy Focus on beta-Lactamase Inhibition
Carine Bebrone et al.
DRUGS (2010)
In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other non-fermenters
Shazad Mushtaq et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2010)
Normalized Resistance Interpretation as a Tool for Establishing Epidemiological MIC Susceptibility Breakpoints
Goran Kronvall
JOURNAL OF CLINICAL MICROBIOLOGY (2010)
In Vitro Activity of NXL104 in Combination with β-Lactams against Klebsiella pneumoniae Isolates Producing KPC Carbapenemases
Andrea Endimiani et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
In vitro activity of the β-lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases
Therese Stachyra et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2009)
NXL104 combinations versus Enterobacteriaceae with CTX-M extended-spectrum β-lactamases and carbapenemases
David M. Livermore et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2008)
Statistical characterisation of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values
J Turnidge et al.
CLINICAL MICROBIOLOGY AND INFECTION (2006)
In vitro activity of AVE1330A, an innovative broad-spectrum non-β-lactam β-lactamase inhibitor
A Bonnefoy et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2004)
分享论文
